284 related articles for article (PubMed ID: 32753690)
1. Complex landscape of alternative splicing in myeloid neoplasms.
Hershberger CE; Moyer DC; Adema V; Kerr CM; Walter W; Hutter S; Meggendorfer M; Baer C; Kern W; Nadarajah N; Twardziok S; Sekeres MA; Haferlach C; Haferlach T; Maciejewski JP; Padgett RA
Leukemia; 2021 Apr; 35(4):1108-1120. PubMed ID: 32753690
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
3. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.
Madan V; Li J; Zhou S; Teoh WW; Han L; Meggendorfer M; Malcovati L; Cazzola M; Ogawa S; Haferlach T; Yang H; Koeffler HP
Am J Hematol; 2020 Feb; 95(2):133-143. PubMed ID: 31680297
[TBL] [Abstract][Full Text] [Related]
4. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
Taylor J; Lee SC
Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
[TBL] [Abstract][Full Text] [Related]
5. Splicing Factor Mutations in Cancer.
Bejar R
Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
[TBL] [Abstract][Full Text] [Related]
6. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
[No Abstract] [Full Text] [Related]
7. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia.
Shiozawa Y; Malcovati L; Gallì A; Sato-Otsubo A; Kataoka K; Sato Y; Watatani Y; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Makishima H; Shiraishi Y; Chiba K; Hellström-Lindberg E; Miyano S; Ogawa S; Cazzola M
Nat Commun; 2018 Sep; 9(1):3649. PubMed ID: 30194306
[TBL] [Abstract][Full Text] [Related]
8. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome.
Madan V; Kanojia D; Li J; Okamoto R; Sato-Otsubo A; Kohlmann A; Sanada M; Grossmann V; Sundaresan J; Shiraishi Y; Miyano S; Thol F; Ganser A; Yang H; Haferlach T; Ogawa S; Koeffler HP
Nat Commun; 2015 Jan; 6():6042. PubMed ID: 25586593
[TBL] [Abstract][Full Text] [Related]
9. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
10. Splicing factor mutant myelodysplastic syndromes: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
[TBL] [Abstract][Full Text] [Related]
11. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
[TBL] [Abstract][Full Text] [Related]
12. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
[TBL] [Abstract][Full Text] [Related]
13. Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.
Shingai N; Harada Y; Iizuka H; Ogata Y; Doki N; Ohashi K; Hagihara M; Komatsu N; Harada H
Int J Hematol; 2018 Dec; 108(6):598-606. PubMed ID: 30353274
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic Insights of Aberrant Splicing with Splicing Factor Mutations Found in Myelodysplastic Syndromes.
Kataoka N; Matsumoto E; Masaki S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360561
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
Malcovati L; Cazzola M
Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
[TBL] [Abstract][Full Text] [Related]
16. Spliceosomal factor mutations and mis-splicing in MDS.
Hershberger CE; Daniels NJ; Padgett RA
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
[TBL] [Abstract][Full Text] [Related]
17. [Splicing factor mutations in myelodysplastic syndromes].
Shiozawa Y
Rinsho Ketsueki; 2018; 59(5):566-573. PubMed ID: 29877248
[TBL] [Abstract][Full Text] [Related]
18. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
19. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
Janusz K; Del Rey M; Abáigar M; Collado R; Ivars D; Hernández-Sánchez M; Valiente A; Robledo C; Benito R; Díez-Campelo M; Ramos F; Kohlmann A; Cañizo CD; Hernández-Rivas JM
Leuk Res; 2017 May; 56():82-87. PubMed ID: 28222336
[TBL] [Abstract][Full Text] [Related]
20. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
